Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.

Haslam A, Prasad V. · 2019

Read Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. by Haslam A, Prasad V. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6503493.txt.

Description

Haslam and Prasad estimate how many US cancer patients could use, and gain from, checkpoint inhibitor drugs, writing in JAMA Network Open. These immune drugs drew wide praise, but no one had measured their reach across all cancers. The authors used FDA approval labels plus national cancer death counts as a stand-in for advanced disease.

Eligibility grew fast as approvals piled up. It rose from 1.54% of patients in 2011 to 43.63% in 2018. The share expected to respond rose from 0.14% to 12.46% over the same years. That tops the under-5% benefit once estimated for genome-driven drugs. Yet the authors stress the gains stay modest next to the hype around this drug class.

Catalog record

CREATORHaslam A, Prasad V.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE23 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6503493

Browse the full library · About the Tower of Babel